|
US2631173A
(en)
|
1949-01-04 |
1953-03-10 |
Phillips Petroleum Co |
Production of cyclooctadiene
|
|
IL54795A
(en)
|
1978-05-26 |
1980-10-26 |
Yeda Res & Dev |
Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
|
|
WO1989007970A1
(en)
|
1988-03-02 |
1989-09-08 |
Uab Research Foundation |
Reversible mechanochemical engines comprised of bioelastomers capable of modulable inverse temperature transitions for the interconversion of chemical and mechanical work
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
BRPI0008131B8
(pt)
|
1999-02-12 |
2021-05-25 |
Daiichi Sankyo Co Ltd |
composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
|
|
EP1264826B1
(en)
|
2000-02-22 |
2005-03-30 |
Banyu Pharmaceutical Co., Ltd. |
Novel imidazoline compounds
|
|
JP2002253259A
(ja)
|
2001-03-02 |
2002-09-10 |
Bio Applied Systems:Kk |
抗ビスフェノールａ抗体をコードする遺伝子、組換えタンパク質およびその製造方法
|
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
ES2283759T3
(es)
|
2002-01-18 |
2007-11-01 |
Pierre Fabre Medicament |
Anticuerpos anti-igf-ir y sus aplicaciones.
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
EP1432724A4
(en)
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
RNA inhibition mediated inhibition of MAP KINASE GENES
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US7575886B2
(en)
|
2002-03-11 |
2009-08-18 |
Momenta Pharmaceuticals, Inc. |
Analysis of sulfated polysaccharides
|
|
EP2284269B1
(en)
|
2002-11-18 |
2017-08-09 |
Roche Innovation Center Copenhagen A/S |
Antisense design
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
WO2004058717A1
(en)
|
2002-12-20 |
2004-07-15 |
X-Ceptor Therapeutics, Inc. |
Isoquinolinone derivatives and their use as therapeutic agents
|
|
CA2515623A1
(en)
|
2003-02-10 |
2004-08-19 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of survivin expression
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
AU2004299053B2
(en)
|
2003-12-15 |
2011-01-06 |
Alexion Pharmaceuticals, Inc. |
Novel anti-DC-SIGN antibodies
|
|
US7541330B2
(en)
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
|
WO2006022688A1
(en)
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Diagnosis of pancreatic cancer by using pancreatic targets
|
|
US7807619B2
(en)
|
2004-11-01 |
2010-10-05 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US8431558B2
(en)
|
2004-11-01 |
2013-04-30 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
WO2006091796A2
(en)
|
2005-02-22 |
2006-08-31 |
Acucela, Inc. |
Compositions and methods for diagnosing and treating retinal diseases
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
WO2007089612A2
(en)
|
2006-01-30 |
2007-08-09 |
President And Fellows Of Harvard College |
Methods and compositions for treating and preventing bacterial infections
|
|
US20070249014A1
(en)
|
2006-02-10 |
2007-10-25 |
Invitrogen Corporation |
Labeling and detection of post translationally modified proteins
|
|
EP2505646A1
(en)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of CRP
|
|
JP6047270B2
(ja)
|
2006-08-11 |
2016-12-21 |
バイオマリン テクノロジーズ ベー．フェー． |
Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
|
|
EP2410053B2
(en)
|
2006-10-18 |
2020-07-15 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds
|
|
EP2149605B1
(en)
|
2007-03-22 |
2013-07-03 |
Santaris Pharma A/S |
Short RNA antagonist compounds for the modulation of target mRNA
|
|
US8580756B2
(en)
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
CA2691673A1
(en)
|
2007-06-29 |
2009-01-08 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
|
JP5718640B2
(ja)
|
2007-08-21 |
2015-05-13 |
アムジエン・インコーポレーテツド |
ヒトｃ−ｆｍｓ抗原結合性タンパク質
|
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US20110250199A1
(en)
|
2008-06-04 |
2011-10-13 |
The Government of the United States of America as represented by the Secretary of the Department.... |
Immunotoxins and uses thereof
|
|
EP3133160B1
(en)
|
2008-10-24 |
2018-12-12 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for dmd
|
|
SI2607484T1
(sl)
|
2008-10-27 |
2016-11-30 |
Biomarin Technologies B.V. |
Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
|
|
CN102459595A
(zh)
|
2009-04-24 |
2012-05-16 |
普罗森那技术公司 |
用于治疗dmd的包含肌苷的寡核苷酸
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
EP2536287A4
(en)
|
2010-02-18 |
2015-10-07 |
Advanced Proteome Therapeutics Inc |
SPECIFIC SITE SIZE OF PROTEINS USING CHEMICAL MODIFICATION TO PROMOTE PROTEIN CONJUGATE FORMATION, PROTEIN DIMER FORMATION, AND AGRAFTED PEPTIDES
|
|
WO2011107989A1
(en)
|
2010-03-01 |
2011-09-09 |
Lostam Biopharmaceuticals Ltd |
Improved therapeutic antibodies against flagellated pseudomonas aeruginosa
|
|
US8734799B2
(en)
|
2010-04-13 |
2014-05-27 |
The Regents Of The University Of California |
Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
|
|
PT2528625E
(pt)
|
2010-04-15 |
2013-10-17 |
Spirogen Sarl |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
US8859629B2
(en)
|
2010-04-27 |
2014-10-14 |
Synaffix B.V. |
Fused cyclooctyne compounds and their use in metal-free click reactions
|
|
SG186451A1
(en)
|
2010-07-12 |
2013-01-30 |
Covx Technologies Ireland Ltd |
Multifunctional antibody conjugates
|
|
ES2756326T3
(es)
|
2010-07-19 |
2020-04-27 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
|
|
CN103443125B
(zh)
|
2010-11-30 |
2019-05-03 |
霍夫曼-拉罗奇有限公司 |
低亲和力血脑屏障受体抗体及其用途
|
|
AU2011349443B2
(en)
|
2010-12-20 |
2015-12-24 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
US10017764B2
(en)
|
2011-02-08 |
2018-07-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
AU2012246822B2
(en)
|
2011-04-22 |
2017-05-25 |
Biomarin Technologies B.V. |
New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1)
|
|
WO2012178173A1
(en)
|
2011-06-24 |
2012-12-27 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
US20130066063A1
(en)
|
2011-09-09 |
2013-03-14 |
John Cooke Hodges |
Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides
|
|
EP2599785A1
(en)
|
2011-11-30 |
2013-06-05 |
Agilent Technologies, Inc. |
Novel methods for the synthesis and purification of oligomers
|
|
EP2788026A4
(en)
|
2011-12-05 |
2015-08-05 |
Univ Duke |
V1V2 IMMUNOGENIC
|
|
CA2858576A1
(en)
|
2011-12-06 |
2013-06-13 |
Research Institute At Nationwide Children's Hospital |
Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
|
|
TW201333040A
(zh)
|
2012-01-06 |
2013-08-16 |
Bioalliance Cv |
抗－輸鐵蛋白受器之抗體及其使用方法
|
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
|
US9610362B2
(en)
|
2012-03-16 |
2017-04-04 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of DMPK
|
|
PT2841578T
(pt)
|
2012-04-23 |
2017-08-10 |
Biomarin Tech Bv |
Resumo
|
|
US10111962B2
(en)
|
2012-09-25 |
2018-10-30 |
Genzyme Corporation |
Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
|
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
HRP20180268T4
(hr)
|
2012-10-23 |
2026-03-27 |
Synaffix B.V. |
Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
|
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
|
ES2731681T3
(es)
|
2013-02-22 |
2019-11-18 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
EP3004062B1
(en)
|
2013-05-24 |
2017-07-19 |
SynAffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
CA2921457A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Heterochromatin forming non-coding rnas
|
|
CA2922544A1
(en)
|
2013-08-28 |
2015-03-05 |
Stemcentrx, Inc. |
Engineered anti-dll3 conjugates and methods of use
|
|
AU2014321211A1
(en)
|
2013-09-23 |
2016-05-05 |
President And Fellows Of Harvard College |
Allele-specific RNA silencing for the treatment of hypertrophic cardiomyopathy
|
|
WO2015057064A1
(en)
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
WO2015057065A1
(en)
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
US10004814B2
(en)
|
2013-11-11 |
2018-06-26 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
|
|
WO2015073848A1
(en)
|
2013-11-14 |
2015-05-21 |
Shehadeh Lina A |
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
|
|
CN106660967A
(zh)
|
2014-01-24 |
2017-05-10 |
西纳福克斯股份有限公司 |
(杂)芳基1，3‑偶极化合物与(杂)环炔的环加成方法
|
|
EP3097080A1
(en)
|
2014-01-24 |
2016-11-30 |
SynAffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
JP6750148B2
(ja)
|
2014-04-25 |
2020-09-02 |
公益財団法人野口研究所 |
糖鎖切断抗体の製造方法及び均一糖鎖抗体
|
|
AR100560A1
(es)
|
2014-05-23 |
2016-10-12 |
Genzyme Corp |
Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido
|
|
EP3177633B1
(en)
|
2014-08-04 |
2022-07-20 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
WO2016025519A1
(en)
|
2014-08-11 |
2016-02-18 |
Shire Human Genetic Therapies, Inc. |
Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
|
|
GB201416960D0
(en)
|
2014-09-25 |
2014-11-12 |
Antikor Biopharma Ltd |
Biological materials and uses thereof
|
|
US10407500B2
(en)
|
2014-09-25 |
2019-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immunological treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
|
|
US9714288B2
(en)
|
2014-09-30 |
2017-07-25 |
The Regents Of The University Of California |
Antisense compounds and uses thereof
|
|
RU2715905C2
(ru)
|
2014-10-01 |
2020-03-04 |
МЕДИММЬЮН, ЭлЭлСи |
Способ конъюгации полипептида
|
|
EP3733209A1
(en)
|
2014-10-03 |
2020-11-04 |
Synaffix B.V. |
Sulfamide linker, conjugates thereof, and methods of preparation
|
|
CA2967830A1
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
Tfr selective binding compounds and related methods
|
|
CA2966932A1
(en)
|
2014-11-19 |
2016-05-26 |
Immunogen, Inc. |
Process for preparing cell-binding agent-cytotoxic agent conjugates
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
AU2015349890B2
(en)
|
2014-11-21 |
2018-08-30 |
Merck Sharp & Dohme Llc |
Insulin receptor partial agonists
|
|
MX2017011004A
(es)
|
2015-02-27 |
2018-02-09 |
Sarepta Therapeutics Inc |
Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida.
|
|
CN107810273B
(zh)
|
2015-04-23 |
2022-09-27 |
西纳福克斯股份有限公司 |
用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
|
|
KR102644053B1
(ko)
|
2015-05-19 |
2024-03-06 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
펩티드 올리고뉴클레오티드 콘주게이트
|
|
CA2990785C
(en)
|
2015-06-24 |
2024-11-12 |
Jcr Pharmaceuticals Co., Ltd. |
ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
|
|
IL257065B
(en)
|
2015-07-22 |
2022-07-01 |
Inatherys |
Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases
|
|
EP3353306A4
(en)
|
2015-09-25 |
2019-06-05 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
MA46427A
(fr)
|
2015-10-09 |
2018-08-15 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
JP2018530560A
(ja)
|
2015-10-09 |
2018-10-18 |
サレプタ セラピューティクス， インコーポレイテッド |
デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
|
|
MY207684A
(en)
|
2015-12-08 |
2025-03-12 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
EP4032902A1
(en)
|
2015-12-18 |
2022-07-27 |
Eisai R&D Management Co., Ltd. |
C-terminal lysine conjugated immunoglobulins
|
|
AR108825A1
(es)
|
2016-02-05 |
2018-10-03 |
Ole Petter Veiby |
Conjugados de anticuerpo y fármaco dirigidos contra gcc
|
|
US10874746B2
(en)
|
2016-02-08 |
2020-12-29 |
Synaffix B.V. |
Sulfamide linkers for use in bioconjugates
|
|
WO2017143156A1
(en)
|
2016-02-19 |
2017-08-24 |
Genisphere Llc |
Nucleic acid carriers and therapeutic methods of use
|
|
MY199595A
(en)
|
2016-03-02 |
2023-11-08 |
Eisai R&D Man Co Ltd |
Eribulin-based antibody-drug conjugates and methods of use
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
FR3049951A1
(fr)
|
2016-04-12 |
2017-10-13 |
Univ Rabelais Francois |
Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
|
|
JP2019516679A
(ja)
|
2016-05-04 |
2019-06-20 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
生物活性剤に関する方法および組成物
|
|
WO2017205191A1
(en)
|
2016-05-24 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Insulin receptor partial agonists and glp-1 analogues
|
|
KR20190014525A
(ko)
|
2016-05-27 |
2019-02-12 |
애브비 바이오테라퓨틱스 인크. |
면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
|
|
DK3473270T5
(da)
|
2016-06-20 |
2024-09-09 |
Genahead Bio Inc |
Konjugat af antistof-lægemiddel
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
TWI833178B
(zh)
|
2016-12-26 |
2024-02-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
KR20240172236A
(ko)
|
2017-01-06 |
2024-12-09 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
|
|
CA3049791A1
(en)
*
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
AU2018281280B2
(en)
|
2017-06-07 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
WO2019023257A1
(en)
|
2017-07-24 |
2019-01-31 |
Quantum-Si Incorporated |
HIGH INTENSITY MARKED REAGENT COMPOSITIONS AND SEQUENCING METHODS
|
|
SG11202002517RA
(en)
|
2017-09-22 |
2020-04-29 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
SG11202003126VA
(en)
|
2017-10-04 |
2020-05-28 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and uses thereof
|
|
US11400165B2
(en)
|
2017-11-04 |
2022-08-02 |
Advanced Proteome Therapeutics Inc. |
Composition and method for modifying polypeptides
|
|
CN118638787A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
EP3735252A4
(en)
|
2018-01-04 |
2021-10-06 |
Avidity Biosciences, Inc. |
HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
|
|
CN111683972A
(zh)
|
2018-02-05 |
2020-09-18 |
Jcr制药股份有限公司 |
用于将药剂递送至肌肉的方法
|
|
CN112040985A
(zh)
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
EP3830127A4
(en)
|
2018-08-02 |
2022-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
CN112955154A
(zh)
|
2018-08-02 |
2021-06-11 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
WO2020028832A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
CN112930193A
(zh)
|
2018-08-02 |
2021-06-08 |
达因疗法公司 |
肌肉靶向复合物及其在治疗肌肉萎缩中的用途
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
AU2019315593B2
(en)
|
2018-08-02 |
2026-05-21 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
US20210322562A1
(en)
|
2018-08-02 |
2021-10-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
CA3108328A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva
|
|
CA3108386A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
EP3829594A4
(en)
|
2018-08-02 |
2022-05-11 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
|
|
EP3830259A4
(en)
|
2018-08-02 |
2022-05-04 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
|
|
IT201800009682A1
(it)
|
2018-10-22 |
2020-04-22 |
Ice Spa |
Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
|
|
EP3876998A1
(en)
|
2018-11-05 |
2021-09-15 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing trop-2
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
SG11202106717PA
(en)
|
2019-02-08 |
2021-07-29 |
Prothena Biosciences Ltd |
Antibodies recognizing tau
|
|
CN113677374A
(zh)
|
2019-04-08 |
2021-11-19 |
国立大学法人东京医科齿科大学 |
肌疾病治疗用药物组合物
|
|
JP7581252B2
(ja)
|
2019-06-06 |
2024-11-12 |
アビディティー バイオサイエンシーズ，インク． |
Ｕｎａアミダイトおよびその使用
|
|
WO2020247782A1
(en)
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
CN114025805B
(zh)
|
2019-06-07 |
2025-01-24 |
达因疗法公司 |
制备蛋白质-寡核苷酸复合物的方法
|
|
US20240148891A1
(en)
|
2019-10-18 |
2024-05-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JP2023503644A
(ja)
|
2019-11-27 |
2023-01-31 |
ディー・ティー・エックス・ファーマ・インコーポレイテッド |
デュシェンヌ型筋ジストロフィーの治療のための化合物および方法
|
|
US20230111212A1
(en)
|
2020-01-10 |
2023-04-13 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
JP7858532B2
(ja)
|
2020-01-10 |
2026-05-14 |
ダイン セラピューティクス，インコーポレーテッド |
筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
|
|
CN122124274A
(zh)
|
2020-01-10 |
2026-06-02 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
|
|
US20230203180A1
(en)
|
2020-01-10 |
2023-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
WO2021142217A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Thereapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of milck1
|
|
WO2021142260A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of acvr1
|
|
WO2021142269A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
|
|
WO2021142331A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
|
|
EP4087653A4
(en)
*
|
2020-01-10 |
2024-06-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CN115427448A
(zh)
|
2020-01-10 |
2022-12-02 |
达因疗法公司 |
肌肉靶向复合物及其用途
|
|
US20230117883A1
(en)
|
2020-01-24 |
2023-04-20 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
WO2021154477A1
(en)
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
IL295022A
(en)
|
2020-01-31 |
2022-09-01 |
Dyne Therapeutics Inc |
Antibody against transferrin receptor and uses thereof
|
|
KR102927945B1
(ko)
|
2020-03-27 |
2026-02-23 |
어비디티 바이오사이언시스 인크. |
근이영양증의 치료용 조성물 및 방법
|
|
US20230330246A1
(en)
|
2020-05-05 |
2023-10-19 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
US12629426B2
(en)
|
2020-07-23 |
2026-05-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
MX2023000984A
(es)
|
2020-07-23 |
2023-05-03 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
AU2021313058A1
(en)
|
2020-07-23 |
2023-03-30 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
CN116348139A
(zh)
|
2020-07-23 |
2023-06-27 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
|
|
US20230256112A1
(en)
|
2020-07-23 |
2023-08-17 |
Dyne Therapeutics, lnc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
MX2023000958A
(es)
|
2020-07-23 |
2023-04-14 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de estos para el tratamiento de la distrofia miotonica.
|
|
EP4185320A4
(en)
|
2020-07-23 |
2025-10-08 |
Dyne Therapeutics Inc |
MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
KR20230079068A
(ko)
|
2020-09-03 |
2023-06-05 |
다인 세라퓨틱스, 인크. |
단백질-올리고뉴클레오티드 복합체의 제조 방법
|
|
AU2021342155A1
(en)
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
|
|
KR20230117182A
(ko)
|
2020-12-04 |
2023-08-07 |
다인 세라퓨틱스, 인크. |
항체-올리고뉴클레오티드 복합체 및 그의 용도
|
|
EP4271478A4
(en)
|
2020-12-31 |
2025-03-26 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR TREATING FACIOSCAPULOHUMERAL MYOPATHY
|
|
AU2021414227A1
(en)
|
2020-12-31 |
2023-07-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
KR20240009393A
(ko)
|
2021-03-31 |
2024-01-22 |
엔트라다 테라퓨틱스, 인크. |
사이클릭 세포 침투 펩티드
|
|
EP4314298A4
(en)
|
2021-04-02 |
2026-06-03 |
Avidity Biosciences Inc |
ANTIBODY-OLIGONUCLEOTIDE CONJUGATES AND ANTIBODY-PEPTIDE-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND EXON-SKIPPING INDUCTION METHODS
|
|
WO2022240758A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
|
CA3222816A1
(en)
|
2021-06-21 |
2022-12-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
EP4359534A4
(en)
|
2021-06-21 |
2026-07-22 |
Dyne Therapeutics Inc |
MUSCLE TARGETTING COMPLEXES AND THEIR USES IN THE TREATMENT OF POMPE DISEASE
|
|
JPWO2022270585A1
(enExample)
|
2021-06-23 |
2022-12-29 |
|
|
|
JP2024525613A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
EP4366774A4
(en)
|
2021-07-09 |
2025-11-19 |
Dyne Therapeutics Inc |
MUSCLE TARGETTING COMPLEXES AND THEIR USES FOR MODULATING GENES ASSOCIATED WITH MUSCLE HEALTH
|
|
CN118591391A
(zh)
|
2021-07-09 |
2024-09-03 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗肌养蛋白病的用途
|
|
US20240318176A1
(en)
|
2021-07-09 |
2024-09-26 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
CA3226301A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3226298A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2023283623A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating dystrophinopathies
|
|
WO2023283629A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
|
|
CN118401553A
(zh)
|
2021-07-09 |
2024-07-26 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗肌养蛋白病的用途
|
|
EP4389891A4
(en)
|
2021-08-19 |
2025-10-29 |
Univ Nat Corp Tokyo Medical & Dental |
MODIFIED HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID
|
|
WO2023026994A1
(ja)
|
2021-08-21 |
2023-03-02 |
武田薬品工業株式会社 |
ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
|
|
IL311507A
(en)
|
2021-09-16 |
2024-05-01 |
Dyne Therapeutics Inc |
Dosing of muscle targeting complexes for the treatment of dystrophinopathy
|
|
EP4426356A1
(en)
|
2021-11-01 |
2024-09-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating dystrophinopathies
|
|
JP2024546436A
(ja)
|
2021-11-12 |
2024-12-24 |
ダイン セラピューティクス，インコーポレーテッド |
顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
|
|
CA3240612A1
(en)
|
2021-12-22 |
2023-06-29 |
Miriam Verena Bujny |
Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
|
|
EP4452281A1
(en)
|
2021-12-22 |
2024-10-30 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
|
|
US20250082759A1
(en)
|
2021-12-22 |
2025-03-13 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
|
|
WO2023168427A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
|
JP2025079347A
(ja)
|
2022-03-11 |
2025-05-22 |
日本新薬株式会社 |
キャリアペプチドが連結された核酸
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
US20250249117A1
(en)
|
2022-04-15 |
2025-08-07 |
Dyne Therapeutics, Inc. |
Dosing of muscle targeting complexes for treating myotonic dystrophy
|
|
WO2023201324A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
AU2023303022A1
(en)
|
2022-07-06 |
2025-01-02 |
Dyne Therapeutics, Inc. |
Cns targeting complexes and uses thereof
|
|
WO2024011135A2
(en)
|
2022-07-06 |
2024-01-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
JP2026503873A
(ja)
|
2022-10-31 |
2026-02-02 |
ダイン セラピューティクス，インコーポレーテッド |
Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用
|
|
IL321025A
(en)
|
2022-11-21 |
2025-07-01 |
Pepgen Inc |
Cell-penetrating peptides, conjugates thereof, and methods of their use
|
|
WO2024149282A1
(en)
|
2023-01-10 |
2024-07-18 |
Ausperbio Therapeutics Inc. |
Modified multi-segmented antisense oligonucleotides for use
|
|
AU2024230817A1
(en)
|
2023-02-27 |
2025-09-11 |
Dyne Therapeutics, Inc. |
Methods and compositions for inhibiting progression of intramuscular fibrosis
|
|
EP4788835A1
(en)
|
2023-10-06 |
2026-08-12 |
Dyne Therapeutics, Inc. |
Biomarkers for repeat expansion diseases
|
|
WO2025137547A1
(en)
|
2023-12-22 |
2025-06-26 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy
|
|
WO2025147541A1
(en)
|
2024-01-02 |
2025-07-10 |
Dyne Therapeutics, Inc. |
Methods and compositions for treating myotonic dystrophy
|
|
WO2025255283A1
(en)
|
2024-06-07 |
2025-12-11 |
Dyne Therapeutics, Inc. |
Dosing of muscle targeting complexes for treating facioscapulohumeral muscular dystrophy
|
|
WO2025259503A1
(en)
|
2024-06-12 |
2025-12-18 |
Dyne Therapeutics, Inc. |
Biomarkers for facioscapulohumeral muscular dystrophy
|
|
WO2025265092A1
(en)
|
2024-06-21 |
2025-12-26 |
Dyne Therapeutics, Inc. |
Complexes and uses thereof for treating pompe disease
|